BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/25/2025 7:54:02 AM | Browse: 11 | Download: 62
 |
Received |
|
2024-07-31 01:39 |
|
Peer-Review Started |
|
2024-07-23 12:37 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-01-08 06:46 |
|
Revised |
|
2025-01-21 09:59 |
|
Second Decision |
|
2025-03-05 03:02 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-03-13 06:42 |
|
Articles in Press |
|
2025-03-13 06:42 |
|
Publication Fee Transferred |
|
2025-01-25 03:22 |
|
Edit the Manuscript by Language Editor |
|
2025-03-18 22:06 |
|
Typeset the Manuscript |
|
2025-04-11 07:41 |
|
Publish the Manuscript Online |
|
2025-04-25 07:54 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Ophthalmology |
| Manuscript Type |
Basic Study |
| Article Title |
Ranibizumab’s effect on diabetic retinopathy via vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ye-Ting Lin, Jian Tan, Yu-Lin Tao, Wei-Wen Hu, Yi-Cang Wang, Jing Huang, Qiong Zhou and Ang Xiao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Jiangxi province |
No. 20242BAB25489 |
| National Natural Science Foundation of China |
No. 82260211 |
| National Natural Science Foundation of China |
No. 81460092 |
| Key Research and Development Project in Jiangxi Province |
No. 20203BBG73058 |
| Chinese Medicine Science and Technology Project in Jiangxi Province |
No. 2020A0166 |
|
| Corresponding Author |
Ang Xiao, PhD, Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, No. 17 Yongwai Zheng Street, Donghu District, Nanchang 330006, Jiangxi Province, China. xiao2818161@126.com |
| Key Words |
Diabetic retinopathy; Ranibizumab; Early stage; Vascular endothelial growth factor; STAT3; Glial fibrillary acidic protein |
| Core Tip |
Diabetic retinopathy (DR) is the leading cause of vision loss in patients with diabetes, yet the mechanisms behind its early stages remain unclear. This study explored the therapeutic effects of intravitreal ranibizumab on early DR through its effect on the vascular endothelial growth factor/STAT3/glial fibrillary acidic protein signaling pathway. Using high-glucose retinal cells and diabetic rat models, ranibizumab suppressed cytokine expression, reduced retinal ganglion cell apoptosis, and repaired vascular networks. These findings highlight the potential of ranibizumab in delaying or preventing early DR progression and provide a foundation for its clinical application. |
| Publish Date |
2025-04-25 07:54 |
| Citation |
<p>Lin YT, Tan J, Tao YL, Hu WW, Wang YC, Huang J, Zhou Q, Xiao A. Ranibizumab’s effect on diabetic retinopathy via vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway. <i>World J Diabetes</i> 2025; 16(5): 99473</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i5/99473.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i5.99473 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
